Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer (Nsclc) in Patients Non-Responsive to Immune Checkpoint Inhibitor (Ici) Treatment at 2024 Asco Annual Meeting
Candel Therapeutics在2024年Asco年會上報告稱，針對對免疫檢查點抑制劑（Ici）治療無反應的患者的晚期非小細胞肺癌（Nsclc）的Can-2409的2期臨床試驗的總存活率延長